NEO's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 292.53 -- higher than 88.19% of US-listed equities with positive expected earnings growth.
Price to trailing twelve month operating cash flow for NEO is currently 273.44, higher than 98.7% of US stocks with positive operating cash flow.
Over the past twelve months, NEO has reported earnings growth of -295.29%, putting it ahead of only 6.42% of US stocks in our set.
Stocks with similar financial metrics, market capitalization, and price volatility to Neogenomics Inc are TREE, HURC, GHSI, CVV, and LOPE.
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. The company was founded in 2001 and is based in Fort Myers, Florida.